Biotech News
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
ir.foghorntx.com2026-05-06 15:04 EST
WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the closing of its $50 million registered